Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Masucci, Giuseppe V ^a   Wersäll, Peter ^a   Kiessling, Rolf ^a   Lundqvist, Andreas ^a   Lewensohn, Rolf ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR;

ADOPTIVE TRANSFER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELL TRANSFER; DENDRITIC CELL; DISTANT METASTASIS; DOSE RESPONSE; DRUG DOSE ESCALATION; HUMAN; IMMUNOREGULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; IONIZING RADIATION; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; METASTASIS; METASTASIS POTENTIAL; NOTE; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; SOLID TUMOR; STEREOTACTIC ABLATIVE RADIATION THERAPY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASM METASTASIS; NEOPLASMS; RADIOTHERAPY;

EID: 84861204770     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-104     Document Type: Note

References (16)

1. Ascierto PA, Marincola FM. Combination therapy: the next opportunity and challenge of medicine. J Transl Med 2011, 9:115. 10.1186/1479-5876-9-115, 3157452, 21777474.
2. Masucci GV, Mansson-Brahme E, Ragnarsson-Olding B, Nilsson B, Wagenius G, Hansson J. Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. Melanoma Res 2006, 16:357-363. 10.1097/01.cmr.0000205019.23612.a1, 16845332.
3. Svedman C, Karlsson K, Rutkowska E, Sandstrom P, Blomgren H, Lax I, Wersall P. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol 2008, 47:1578-1583. 10.1080/02841860802123196, 18607859.
4. Svedman C, Sandstrom P, Pisa P, Blomgren H, Lax I, Kalkner KM, Nilsson S, Wersall P. A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 2006, 45:870-875. 10.1080/02841860600954875, 16982552.
5. Wersall PJ, Blomgren H, Lax I, Kalkner KM, Linder C, Lundell G, Nilsson B, Nilsson S, Naslund I, Pisa P, Svedman C. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 2005, 76:S37-S37.
6. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, Drugge N, Ekberg L, Friesland S, Johansson KA, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009, 27:3290-3296. 10.1200/JCO.2008.21.5681, 19414667.
7. Baumann P, Nyman J, Lax I, Friesland S, Hoyer M, Rehn Ericsson S, Johansson KA, Ekberg L, Morhed E, Paludan M, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncologica 2006, 45:787-795. 10.1080/02841860600904862, 16982541.
8. Siomin V, Lin JL, Marko NF, Barnett GH, Toms SA, Chao ST, Angelov L, Vogelbaum MA, Navaratne K, Suh JH, Weil RJ. Stereotactic radiosurgical treatment of brain metastases to the choroid plexus. Int J Radiat Oncol Biol Phys 2011, 80:1134-1142. 10.1016/j.ijrobp.2010.03.016, 21683888.
9. Zelefsky MJ, Greco C, Motzer R, Magsanoc JM, Pei X, Lovelock M, Mechalakos J, Zatcky J, Fuks Z, Yamada Y. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 2012, 82:1744-1748. 10.1016/j.ijrobp.2011.02.040, 21596489.
10. Severin AC, Heijbel M, Alvevik P, Sorcini B, Wersall P, Furberg M, Naslund I, Castellanos E. Comparison of implanted gold markers and cone beam CT for high precision on-line image-guided radiotherapy of prostate. Radiother Oncol 2006, 81:S214-S214.
11. Snyder AR. Review of radiation-induced bystander effects. Hum Exp Toxicol 2004, 23:87-89. 10.1191/0960327104ht423oa, 15070066.
12. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004, 58:862-870. 10.1016/j.ijrobp.2003.09.012, 14967443.
13. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366:925-931. 10.1056/NEJMoa1112824, 3345206, 22397654.
14. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008, 15:3-12. 10.1038/sj.cdd.4402269, 18007663.
15. Apetoh L, Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Piacentini M, Kroemer G, Zitvogel L. Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells. Cancer Genomics Proteomics 2007, 4:65-70.
16. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009, 15:5379-5388. 10.1158/1078-0432.CCR-09-0265, 2746048, 19706802.